Healthcare Biz Recap: Amylin in FDA HOT WATER, Rosetta Genomics OFFERS Up Shares
Amylin (NASDAQ:AMLN) could be in serious trouble with the FDA, as it’s accused of covering up a study of its Byetta diabetes med, that raised concerns over heart safety, and then putting the agency off when the problems became known. Subsequently, Amylin allegedly lept its investors in the dark, by not informing them that the same study had much to do with the FDA’s rejection of its follow-on diabetes drug Bydureon. However: several major drug firms, among them Novartis (NYSE:NVS), Bristol Myers (NYSE:BMY), Merck (NYSE:MRK) – the big names – are still seeking to acquire Amylin as the auction enters its final stage, says Reuters, with final bids expected to appear at the end of this week.
Don’t Miss: Are Big Box Retail Stocks DYING?
The molecular diagnostics firm Rosetta Genomics (NASDAQ:ROSG) intends to offer as much as $35 million in ordinary shares, bringing in money for its operations and for other purposes. At the same time, New York State has okayed the company’s miRview lung assay for testing on patient samples, as it is the only U.S. state that mandates an independent regulatory review process for lab tests.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.